Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 6/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 6/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 6/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 6/20 | 0.40 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | STAT6 | P42226 | 1/20 | 0.32 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adamantane SCHEMBL28705266 | 0.78 | GRIN2D (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Adamantane SCHEMBL1071737 | 0.78 | L3MBTL1 (0.37) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Adamantane SCHEMBL1206076 | 0.77 | GRIN2D (0.38) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Adamantane SCHEMBL15536146 | 0.75 | ALDH1A1 (0.50) | CYP2C9L3MBTL1 | |
| Adamantane SCHEMBL182780 | 0.75 | ALDH1A1 (0.50) | TSHRCYP2C9L3MBTL1 | |
| Adamantane SCHEMBL14696353 | 0.73 | LMNA (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Adamantane SCHEMBL14778131 | 0.73 | GRIN2D (0.35) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Adamantane SCHEMBL29229320 | 0.71 | LMNA (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Adamantane SCHEMBL12761 | 0.71 | CYP2C9 (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Adamantane SCHEMBL1527414 | 0.71 | CYP2C9 (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111470835-A | Method and process for repairing concrete cracks in road and bridge construction | 杭州市城市建设基础工程有限公司 | 2020-07-31 | — | — | CN | claimed |
| CN-111686075-B | In-situ hydrogel composition taking nano-micelle as cross-linking agent and application thereof | 四川大学 | 2021-09-17 | — | — | CN | disclosed |
| CN-110028439-B | Phthalimide derivative and preparation method and application thereof | 四川大学 | 2020-11-13 | — | — | CN | disclosed |
| CN-111686075-A | In-situ hydrogel composition taking nano-micelle as cross-linking agent and application thereof | 四川大学 | 2020-09-22 | — | — | CN | disclosed |
| CN-111470835-A | Method and process for repairing concrete cracks in road and bridge construction | 杭州市城市建设基础工程有限公司 | 2020-07-31 | — | — | CN | disclosed |
| CN-104203928-B | Triazineon compounds and T-shaped calcium channel blocker | 日产化学工业株式会社 | 2017-06-06 | — | — | CN | disclosed |
| US-20160028177-A1 | ELECTRIC CONNECTION STRUCTURE AND TERMINAL | AUTONETWORKS TECHNOLOGIES, LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20130072553-A1 | DRUGS, DERIVATIVES AND ANALOGS CONTAINING ADAMANTANE STRUCTURES OF NEW INDICATION APPLICATIONS OF ANTI-TUMOR | XU LIFENG (US) | 2013-03-21 | — | — | US | disclosed |
| US-6407137-B2 | A PRODRUG COMPOUND CAPABLE OF FACILITATING THE PASSAGE OF A DRUG ACROSS THE BLOOD BRAIN BARRIER COMPRISING A FATTY ACID COUPLED TO A DRUG TO FORM A PRODRUG | PROTARGA, INC. | 2002-06-18 | — | — | US | disclosed |
| US-20010056116-A1 | Dopamine analog amide | LUITPOLD PHARMACEUTICALS, INC. | 2001-12-27 | — | — | US | disclosed |
| US-6107499-A | FACILITATING THE TRANSPORT OF A NEUROTRANSMITTER ACROSS THE BLOOD BRAIN BARRIER BY ADMINISTERING THE DRUG, A NEUROTRANSMITTER SUCH AS DOPAMINE COVALENTLY COUPLED TO A SINGLE, STRAIGHT-CHAINED FATTY ACID CARRIER MOLECULE | NEUROMEDICA, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-5994392-A | PASSAGE OF DRUG THROUGH BLOOD BRAIN BARRIER | NEUROMEDICA, INC. (US) | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072553-A1 | DRUGS, DERIVATIVES AND ANALOGS CONTAINING ADAMANTANE STRUCTURES OF NEW INDICATION APPLICATIONS OF ANTI-TUMOR | ADA, GBA1, ADAM8 | GRIN2D 956/4885GRIN3B 209/4885GRIN1 151/4885 |
| US-20010056116-A1 | Dopamine analog amide | FABP7, SLC6A3, ALOX15 | GRIN2D 532/4885GRIN3B 250/4885GRIN1 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.